POPA Recon✔️Moderna surges 100%, succeeds in Phase 3 cancer vaccine
✔️Moderna surges 100%, succeeds in Phase 3 cancer vaccine The personalized mRNA cancer vaccine mRNA-4157/V940, which is being jointly developed by Moderna and Merck, announced positive results in Phase 3 clinical trials targeting melanoma. • Significantly improved recurrence-free survival (RFS) • Distant metastasis-free survival (DMFS) also improved. • No new safety issues • Approval process to be discussed with regulatory authorities With this news, the market soared by 100%. Related articles
The excerpt is quoted from a public Telegram channel, which owns its text.